Department of Nephrology and Renal Transplantation, Hospital Clínic of Barcelona, Barcelona, Spain.
Laboratori Experimental de Nefrologia i Trasplantament (LENIT), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Nephrology (Carlton). 2021 Sep;26(9):742-747. doi: 10.1111/nep.13907. Epub 2021 Jun 5.
Early graft loss is a devastating kidney transplant complication associated with high mortality and an increased risk of sensitization to antigens from the failed graft. Moreover, if rapid re-transplantation were to occur, given that the human leukocyte antigen antibodies identification may not be reliable until several weeks after transplantation, the recipient's immunological status would be uncertain. Hence, there could be an increased immunological risk. To date, there is no information on whether a rapid re-transplantation after early graft loss, without a new reliable anti-HLA determination, is safe.
We retrospectively analysed the number of rejections and the graft survival of re-transplanted patients with early graft loss (defined as graft failure before 30 days from transplant) from our centre between June 2003 and November 2019. The studied population was divided into rapid re-transplantation (performed within 30 days of early graft loss) and late re-transplantation (performed beyond those 30 days).
Forty-seven patients were re-transplanted after early graft loss. There were nine rapid re-transplantation cases with an 89% five-year graft survival and one antibody-mediated rejection episode. Furthermore, we identified 38 cases of late re-transplantation with a 69% five-year graft survival, 4 T cell-mediated, and 11 antibody-mediated rejections.
Rapid re-transplantation appears to be safe and does not entail increased rejection risk, nor does it impact long-term graft survival when compared to late re-transplantation.
早期移植物失功是一种毁灭性的肾移植并发症,与高死亡率和增加对失败移植物抗原致敏的风险相关。此外,如果发生快速再次移植,由于人类白细胞抗原抗体的鉴定可能要在移植后数周才可靠,受者的免疫状态将不确定。因此,可能存在增加的免疫风险。迄今为止,尚无关于在早期移植物失功后是否可以在没有新的可靠抗 HLA 测定的情况下快速再次移植的信息。
我们回顾性分析了 2003 年 6 月至 2019 年 11 月期间我们中心早期移植物失功(定义为移植后 30 天内移植物失功)的再次移植患者的排斥反应次数和移植物存活率。研究人群分为快速再次移植(在早期移植物失功后 30 天内进行)和晚期再次移植(在 30 天后进行)。
47 例患者在早期移植物失功后进行了再次移植。有 9 例快速再次移植,5 年移植物存活率为 89%,发生 1 例抗体介导的排斥反应。此外,我们发现 38 例晚期再次移植,5 年移植物存活率为 69%,发生 4 例 T 细胞介导的排斥反应和 11 例抗体介导的排斥反应。
与晚期再次移植相比,快速再次移植似乎是安全的,不会增加排斥反应的风险,也不会影响长期移植物存活率。